Edition:
United States

Accuray Inc (ARAY.OQ)

ARAY.OQ on NASDAQ Stock Exchange Global Select Market

4.35USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$4.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
110,180
52-wk High
$6.15
52-wk Low
$3.60

Chart for

About

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife... (more)

Overall

Beta: 1.69
Market Cap(Mil.): $372.53
Shares Outstanding(Mil.): 85.64
Dividend: --
Yield (%): --

Financials

  ARAY.OQ Industry Sector
P/E (TTM): -- 38.09 34.18
EPS (TTM): -0.33 -- --
ROI: -17.19 8.73 13.17
ROE: -62.52 12.61 15.15

BRIEF-Accuray Q3 Loss Per Share $0.10

* Q3 EARNINGS PER SHARE VIEW $-0.05 -- THOMSON REUTERS I/B/E/S

Apr 30 2018

BRIEF-Apollo Hospitals In India To Acquire Two Accuray Radixact Systems

* APOLLO HOSPITALS IN INDIA TO ACQUIRE TWO ACCURAY RADIXACT® SYSTEMS

Mar 28 2018

BRIEF-Accuray Retires February 2018 Convertible Notes

* ACCURAY RETIRES FEBRUARY 2018 CONVERTIBLE NOTES Source text for Eikon: Further company coverage:

Feb 05 2018

BUZZ-Accuray: RBC, Jefferies raise PTs after results

** Radiation and oncology device maker's shares up 7.69 pct at $5.6 premarket

Jan 24 2018

BRIEF-Accuray Reports Q2 Loss Per Share $0.06

* ACCURAY FISCAL SECOND QUARTER REVENUE EXCEEDS $100 MILLION AND INCREASES 15 PERCENT YEAR-OVER-YEAR; GROSS ORDERS OF $77.9 MILLION; BACKLOG UP 10 PERCENT

Jan 23 2018

BRIEF-Beverly Huss Joins Accuray Board Of Directors

* ACCURAY INC - WITH APPOINTMENT OF HUSS, CO'S BOARD CONSISTS OF SEVEN MEMBERS Source text for Eikon: Further company coverage:

Jan 11 2018

BRIEF-Accuray Elects Net Share Settlement For 3.50 Pct Series A Convertible Senior Notes

* ACCURAY ELECTS NET SHARE SETTLEMENT FOR 3.50% SERIES A CONVERTIBLE SENIOR NOTES DUE 2018

Jan 03 2018

Competitors

Earnings vs. Estimates